论文部分内容阅读
目的:探讨依达拉奉联合高压氧治疗一氧化碳中毒迟发性脑病(DEACMP)的临床疗效。方法:将64例DEACMP患者随机分为治疗组及对照组各32例。对照组给予高压氧、减轻脑水肿等常规治疗,治疗组在常规治疗基础上加用依达拉奉30 mg/次,2次/d静脉滴注,治疗30 d。监测血清丙二醛(MDA)浓度,治疗前后均用(NIHSS)量表检测评分。结果:治疗组治疗后(MDA)浓度较治疗前明显降低(P<0.05),对照组变化不明显(P>0.05)。治疗组临床症状改善明显高于对照组(P<0.05)。结论:依达拉奉联合高压氧治疗(DEACMP)有显著的预防和治疗效果。
Objective: To investigate the clinical efficacy of edaravone and hyperbaric oxygen in the treatment of delayed carbon monoxide poisoning encephalopathy (DEACMP). Methods: 64 patients with DEACMP were randomly divided into treatment group and control group, 32 cases each. The control group was given hyperbaric oxygen and cerebral edema were relieved. The treatment group was treated with edaravone 30 mg once daily twice daily for 30 days. The concentration of serum malondialdehyde (MDA) was monitored. The scores were measured by NIHSS before and after treatment. Results: After treatment, the concentration of MDA in the treatment group was significantly lower than that before treatment (P <0.05), but not in the control group (P> 0.05). The improvement of clinical symptoms in the treatment group was significantly higher than that in the control group (P <0.05). Conclusion: Edaravone combined with hyperbaric oxygen therapy (DEACMP) has significant preventive and therapeutic effects.